Bio-Rad Laboratories, Inc. (BIO-B)
Price:
310.70 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Edwards Lifesciences Corporation
VALUE SCORE:
6
2nd position
Stryker Corporation
VALUE SCORE:
9
The best
Abbott Laboratories
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
NEWS

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
seekingalpha.com
2025-08-07 07:30:00The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
benzinga.com
2025-08-01 11:30:23Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
reuters.com
2024-10-30 18:09:54Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clinical diagnostics products sales growth.

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
reuters.com
2024-08-01 17:56:40Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
reuters.com
2024-05-07 18:11:01Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.

Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending
reuters.com
2023-10-26 17:46:56Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares down about 11% in extended trading.
No data to display

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
seekingalpha.com
2025-08-07 07:30:00The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
benzinga.com
2025-08-01 11:30:23Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
reuters.com
2024-10-30 18:09:54Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clinical diagnostics products sales growth.

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
reuters.com
2024-08-01 17:56:40Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
reuters.com
2024-05-07 18:11:01Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.

Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending
reuters.com
2023-10-26 17:46:56Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares down about 11% in extended trading.










